Last reviewed · How we verify

NCT03745066

BioFreedom French Registry

Status unknown Last updated 26 April 2021
What this trial tests

trial in Coronary Artery Disease in 1,500 participants. Status unknown.

Timeline
4 April 2019
Primary endpoint
30 April 2021
27 April 2022

Quick facts

Lead sponsorBiosensors Europe SA
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment1,500
Start date4 April 2019
Primary completion30 April 2021
Estimated completion27 April 2022
Sites6 locations across France

Conditions studied

Sponsor

Biosensors Europe SA — full company profile →

Who can join

Eligibility, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, observational multi-center registry to be conducted at up to 25 French interventional cardiology centers. Patients will be eligible once they have received at least one BioFreedomTM DCS as per standard clinical practice and will be followed for up to 2 years post PCI for data collection. The purpose of the registry is to explore the safety and effectiveness of the BioFreedomTM DCS in standard clinical practice in France and to serve as part of Post Market Surveillance.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other Biosensors Europe SA trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03745066.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing